The China Securities Regulatory Commission announced that on January 8th, Jiangsu Chuangjian Medical Technology Co., Ltd. (hereafter referred to as “Trautec”) signed a guidance agreement with CITIC Securities, officially initiating the IPO process for A-shares.
Trautec is dedicated to the research and development as well as the production of recombinant collagen-based biomaterials. It holds five authorized core sequence patents for recombinant collagen. The company has research and development bases and production factories in Wujin and Jintan in Changzhou, Jiangsu, Xining in Qinghai, and Changsha in Hunan, leading the recombinant collagen industry in China.
According to its official website, Trautec currently has three main business segments:
- Biomaterials. This mainly includes the scaled and standardized production of Type I, III, and XVII recombinant collagen.
- Medical/Cosmetic End Products. This includes the Yuebai and Yuebai See Sense brands, covering dressings, gels, repair fluids, etc.
- ODM Cooperation. Trautec provides customized development and production services for medical dressings and cosmetics for clients.
As per the announcement, Trautec was established in Changzhou, Jiangsu in June 2015, with a registered capital of 41.58 million yuan. The controlling shareholder is the founder and CEO Qian Song, who directly holds 48.43% of the shares in Trautec.
In July 2022, Trautec completed nearly 200 million yuan in Series A financing, led by Shiseido’s Ziyue Fund, with Hua Fang Capital, Dinghui Baifu, and Huali Pharmaceuticals participating. The Ziyue Fund, established in collaboration between Shiseido and the asset management company Boyu Investment, is China’s first specialty investment fund by an international beauty group, focusing on investment opportunities in emerging brands and related technologies in the beauty and health markets.
In September 2023, Trautec announced that it had received Series B investment exceeding 200 million yuan. This round was co-led by the L Catterton‘s first RMB fund, which focuses on the entire lifecycle of consumer investments, and the global dollar private equity investment platform of CITIC Securities – CLSA Capital. Other participants included CDF-Capital Investment and MingFeng Capital.
| Source: China Securities Regulatory Commission, Trautec Official Website
| Image Credit: Trautec Official Website
| Editor: LeZhi